Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Astegolimab or Efmarodocokin Alfa in Patients With Severe COVID-19 Pneumonia: A Randomized, Phase 2 Trial.
Waters M, McKinnell JA, Kalil AC, Martin GS, Buchman TG, Theess W, Yang X, Lekkerkerker AN, Staton T, Rosenberger CM, Pappu R, Wang Y, Zhang W, Brooks L, Cheung D, Galanter J, Chen H, Mohan D, Peck MC; COVID-astegolimab-interleukin (IL) (COVASTIL) Study Group. Waters M, et al. Among authors: lekkerkerker an. Crit Care Med. 2023 Jan 1;51(1):103-116. doi: 10.1097/CCM.0000000000005716. Epub 2022 Nov 14. Crit Care Med. 2023. PMID: 36519984 Free PMC article. Clinical Trial.
Population pharmacokinetics and pharmacodynamics of efmarodocokin alfa (IL-22Fc).
Yu Y, Rothenberg ME, Ding HT, Brekkan A, Sperinde G, Harder B, Zhang R, Owen R, Kassir N, Lekkerkerker AN. Yu Y, et al. Among authors: lekkerkerker an. J Pharmacokinet Pharmacodyn. 2024 Apr;51(2):141-153. doi: 10.1007/s10928-023-09888-2. Epub 2023 Oct 20. J Pharmacokinet Pharmacodyn. 2024. PMID: 37864000
Sialic Acid Mediated Endothelial and Hepatic Uptake: A Mechanism based Mathematic Model Elucidating the Complex Pharmacokinetics and Pharmacodynamics of Efmarodocokin Alfa, a Variably Glycosylated Fusion Protein.
Tao X, Sukumaran S, Sperinde G, Liu C, Beardsley MI, Day P, Kalo M, Ayewoh E, Cai H, Wang Y, Jun I, Hirst K, Nguyen V, Chung S, Lee D, Lekkerkerker A, Stefanich E. Tao X, et al. J Pharm Sci. 2024 Mar 30:S0022-3549(24)00100-X. doi: 10.1016/j.xphs.2024.03.016. Online ahead of print. J Pharm Sci. 2024. PMID: 38561054 Free article.
A phase I, randomized, ascending-dose study to assess safety, pharmacokinetics, and activity of GDC-8264, a RIP1 inhibitor, in healthy volunteers.
Jones NS, Kshirsagar S, Mohanan V, Ramakrishnan V, Di Nucci F, Ma L, Mao J, Ding H, Klabunde S, Vucic D, Pan L, Lekkerkerker AN, Chen Y, Rothenberg ME. Jones NS, et al. Among authors: lekkerkerker an. Clin Transl Sci. 2023 Oct;16(10):1997-2009. doi: 10.1111/cts.13607. Epub 2023 Aug 24. Clin Transl Sci. 2023. PMID: 37596814 Free PMC article. Clinical Trial.
SAkuraBONSAI: Protocol design of a novel, prospective study to explore clinical, imaging, and biomarker outcomes in patients with AQP4-IgG-seropositive neuromyelitis optica spectrum disorder receiving open-label satralizumab.
Bennett JL, Fujihara K, Kim HJ, Marignier R, O'Connor KC, Sergott RC, Traboulsee A, Wiendl H, Wuerfel J, Zamvil SS, Anania VG, Buffels R, Künzel T, Lekkerkerker AN, Lennon-Chrimes S, Pittock SJ. Bennett JL, et al. Among authors: lekkerkerker an. Front Neurol. 2023 Feb 17;14:1114667. doi: 10.3389/fneur.2023.1114667. eCollection 2023. Front Neurol. 2023. PMID: 36873431 Free PMC article.
Antibacterial Defense of Human Airway Epithelial Cells from Chronic Obstructive Pulmonary Disease Patients Induced by Acute Exposure to Nontypeable Haemophilus influenzae: Modulation by Cigarette Smoke.
Amatngalim GD, Schrumpf JA, Henic A, Dronkers E, Verhoosel RM, Ordonez SR, Haagsman HP, Fuentes ME, Sridhar S, Aarbiou J, Janssen RAJ, Lekkerkerker AN, Hiemstra PS. Amatngalim GD, et al. Among authors: lekkerkerker an. J Innate Immun. 2017;9(4):359-374. doi: 10.1159/000455193. Epub 2017 Feb 8. J Innate Immun. 2017. PMID: 28171878 Free PMC article.
16 results